GCIA
ABVX

Gabelli & Co Investment Advisers’s Abivax ABVX Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,625
Closed -$219K – 298
2025
Q4 		$219K Buy
+1,625
New +$177K 0.03% 214

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Gabelli & Co Investment Advisers's ABVX Position: Q1 2026 in Review

Gabelli & Co Investment Advisers sold out of Abivax (ABVX) in Q1 2026, closing a stake of 1,625 shares — an estimated $219K sold.

Gabelli & Co Investment Advisers first reported a position in ABVX in Q4 2025 and held it in 1 quarter. The position peaked at $219K in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Gabelli & Co Investment Advisers reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 1,625 Abivax shares in Q1 2026, an estimated $219K.
  • Gabelli & Co Investment Advisers first reported a position in Abivax in Q4 2025 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Abivax position peaked at $219K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.